Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Arthritis Rheumatol. 2021 Feb 8;73(3):520–529. doi: 10.1002/art.41536

Figure 3. Effect of iloprost on Endo-MT in ECs.

Figure 3.

Normal ECs were treated with 10 ng/ml TGFβ and/or 150 nM of iloprost for 3 days. BV9 was added 30 min before the addition of various treatments. Cellular markers for Endo-MT were measured using qPCR. (A) Iloprost inhibited TGFβ-induced Endo-MT in normal ECs, and the effect was blocked by BV9, a VE-cadherin antibody; (B) Iloprost inhibited the Endo-MT phenotype in SSc ECs. Experiments were done with 3–7 subject-derived lines. Results are expressed as mean +/− SD and p<0.05 was considered significant.